Trial Profile

DLCL002 Protocol for Young Patients With Newly Diagnosed High Risk Aggressive B-cell Lymphoma, a Multicenter Phase II Study

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 18 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cisplatin (Primary) ; Cyclophosphamide (Primary) ; Cytarabine (Primary) ; Dexamethasone (Primary) ; Doxorubicin (Primary) ; Etoposide (Primary) ; Lenalidomide (Primary) ; Lenalidomide (Primary) ; Rituximab (Primary) ; Vincristine (Primary)
Indications B-cell lymphoma; Diffuse large B cell lymphoma
Focus Therapeutic Use

Most Recent Events

24 Jan 2022 Planned End Date changed from 1 Feb 2023 to 1 Sep 2024.
24 Jan 2022 Planned primary completion date changed from 1 Feb 2022 to 1 Sep 2023.
19 Feb 2019 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com